FIELD: medicine.
SUBSTANCE: invention relates to medicine, particularly to immunology, and aims at predicting clinical course of vaccination process in children with neurological disorders of central nervous system. For this purpose, before vaccination blood serum is examined for lymphocyte count and their subpopulations CD3, CD4, CD20, interleukin 4, interferon γ IFN-γ and total pool of immunoglobulin IgG. Then derived data are used to group immune responsiveness. For values: lymphocyte count ≥50%, subpopulations CD3 - ≥60%, CD4 - ≥35%, CD20 - ≥25%, IL4≥50 pkg/ml, IFN-γ≥50 pkg/ml, total pool of IgG≥9.5 g/l - predict development of strong reactions of vaccine corresponding to a group of hyper-reactivity. When lymphocytes count ≤45%, CD3 - ≤60%, CD4 - ≤35%, CD20 - ≤21% IL4≤20 pkg/ml, IFN - γ≤50 pkg/ml, total pool of IgG≤5.5 g/l - predict morbidity during vaccination process corresponding hyporeactivity group. When lymphocyte count ≥50%, CD3 - ≤60%, CD4 - ≤35%, CD20 - ≥25%, IL4≤20 pkg/ml, IFN-γ≤50 pkg/ml, total pool of IgG≤5.5 g/l - predict development of both of vaccine reactions and morbidity of vaccination period corresponding to a mixed group.
EFFECT: using present method enables to establish exact prognostic criteria of clinical course of vaccination period which promotes timely use of individual circuits vaccination or revaccination and provides safety grafts in children suffering central nervous system.
1 cl, 5 ex, 1 tbl
